{"id":906265,"date":"2025-11-05T19:31:18","date_gmt":"2025-11-06T00:31:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/"},"modified":"2025-11-05T19:31:18","modified_gmt":"2025-11-06T00:31:18","slug":"ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/","title":{"rendered":"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">COPENHAGEN, Denmark, Nov.  05, 2025  (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on November 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2025 financial results.<\/p>\n<p align=\"left\">Those who would like to participate may access the live webcast <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1eXSGq4YYOnJX7T1v5TpUmuE5CSY8NzaNc1AFGXWjodXZnx33m-U7aydm_O7Q5EPbh-sy7MuQJIOdPHgwb5Lhf4iSh149QozDiCZy-5hPlE=\" rel=\"nofollow\" target=\"_blank\">here<\/a>, or register in advance for the teleconference <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1eXSGq4YYOnJX7T1v5TpUk0KH6VLjzMUCan5dcLYALY0HzuFP8xc6aPYHFUyXg4gkTTRZfx_U9ChTVFwtUNinjefKjOf4F74WhV96K0_e9QpFkLwgosjjCGLSB8IC9Oe05jPQU_IhXlTJNocRn8BaAok2EYKYdcqtf6wZi1PDQw=\" rel=\"nofollow\" target=\"_blank\">here<\/a>. The link to the live webcast will also be available on the Investors &amp; News section of the Ascendis Pharma website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n-CN8_nxZM-nIz6fAWOjRjRDXRIF8kZzOMh0S2IxyWlakUR8-UzMYF_sD-wYG_ZfREt9fT1GfhPydLte5qcpb7-951VM5-DmUa_SyqdQJPULTv5qSyzdD21v2T6fxJFFittvSGjMdRcR_NuBc2DkDQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.ascendispharma.com<\/a>. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days.<\/p>\n<p align=\"left\">\n        <strong>About Ascendis Pharma A\/S<\/strong>\u00a0<br \/>Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OEHUFvJDGQHfUqNevHbJduswTGfwsEOs2K07Gc_80grabWy7iCmZobD2gztQaI3XghXARLyclMgtE3-Y2WylHKmrGzq3IBM0QY4qX0pFXQw=\" rel=\"nofollow\" target=\"_blank\"><u>ascendispharma.com<\/u><\/a> to learn more.\u00a0<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis\u2019 future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis\u2019 plan to report financial results, provide a business update and host a conference call and live webcast on a certain date, (ii) Ascendis\u2019 ability to apply its TransCon technology platform to make a meaningful difference for patients and (iii) Ascendis\u2019 application of TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis\u2019 products and product candidates; unforeseen safety or efficacy results in Ascendis\u2019 development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis\u2019 development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis\u2019 business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis\u2019 ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis\u2019 business in general, see Ascendis\u2019 Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis\u2019 other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.<\/p>\n<p align=\"left\">\n        <em>Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. \u00a9 November 2025 Ascendis Pharma A\/S.<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">\n            <strong><br \/>\n              <u>Investor Contacts:<\/u><br \/>\n            <\/strong><br \/>\n            <br \/>Chad Fugere<br \/>Ascendis Pharma<br \/><a href=\"mailto:ir@ascendispharma.com\" rel=\"nofollow\" target=\"_blank\">ir@ascendispharma.com<\/a><\/p>\n<p>Patti Bank<br \/>ICR Healthcare<br \/>+1 (415) 513-1284<br \/><a href=\"mailto:patti.bank@icrhealthcare.com\" rel=\"nofollow\" target=\"_blank\">patti.bank@icrhealthcare.com<\/a><\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">\n            <strong><br \/>\n              <u>Media Contact:<br \/><\/u><br \/>\n            <\/strong>Melinda Baker<br \/>Ascendis Pharma<br \/><a href=\"mailto:media@ascendispharma.com\" rel=\"nofollow\" target=\"_blank\">media@ascendispharma.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDk2Yzc4YTMtYTk2OC00MmM3LWFjMzYtN2NiOTk5YzYwNjNjLTEwMjI4MDctMjAyNS0xMS0wNS1lbg==\/tiny\/Ascendis-Pharma.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on November 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors &amp; News section of the Ascendis Pharma website at https:\/\/investors.ascendispharma.com. A replay of the webcast &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-906265","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on November 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors &amp; News section of the Ascendis Pharma website at https:\/\/investors.ascendispharma.com. A replay of the webcast &hellip; Continue reading &quot;Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-06T00:31:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025\",\"datePublished\":\"2025-11-06T00:31:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/\"},\"wordCount\":678,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/\",\"name\":\"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=\",\"datePublished\":\"2025-11-06T00:31:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/","og_locale":"en_US","og_type":"article","og_title":"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Market Newsdesk","og_description":"COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) &#8212; Ascendis Pharma A\/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on November 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors &amp; News section of the Ascendis Pharma website at https:\/\/investors.ascendispharma.com. A replay of the webcast &hellip; Continue reading \"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-06T00:31:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025","datePublished":"2025-11-06T00:31:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/"},"wordCount":678,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/","name":"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=","datePublished":"2025-11-06T00:31:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTcxNCM3MjQ3MTkzIzIwMTEyMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/906265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=906265"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/906265\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=906265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=906265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=906265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}